Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:AMAMNASDAQ:CMPINASDAQ:FENCNASDAQ:IPHA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAMAMAmbrx Biopharma$28.00$27.94$6.55▼$28.15$1.77B-1.922.12 million shsN/ACMPICheckmate Pharmaceuticals$10.50$10.46$2.00▼$10.50$231.40M-4.81142,261 shsN/AFENCAdherex Technologies$8.25-0.4%$7.26$3.96▼$8.72$227.70M0.492,477 shs196,816 shsIPHAInnate Pharma$1.85-3.1%$2.08$1.29▼$3.51$170.53M0.26187,219 shs3,484 shs12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAMAMAmbrx Biopharma0.00%0.00%0.00%0.00%0.00%CMPICheckmate Pharmaceuticals0.00%0.00%0.00%0.00%0.00%FENCAdherex Technologies0.00%+6.31%+1.85%+26.92%+37.04%IPHAInnate Pharma0.00%+2.78%-15.91%-5.56%-8.42%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAMAMAmbrx BiopharmaN/AN/AN/AN/AN/AN/AN/AN/ACMPICheckmate PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AFENCAdherex Technologies2.4557 of 5 stars3.61.00.00.02.73.30.0IPHAInnate Pharma3.2376 of 5 stars3.85.00.00.02.71.70.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAMAMAmbrx Biopharma 0.00N/AN/AN/ACMPICheckmate Pharmaceuticals 0.00N/AN/AN/AFENCAdherex Technologies 3.25Buy$13.0057.58% UpsideIPHAInnate Pharma 3.50Strong Buy$11.00494.59% UpsideCurrent Analyst Ratings BreakdownLatest CMPI, IPHA, AMAM, and FENC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/20/2025FENCAdherex TechnologiesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$13.00 ➝ $13.005/14/2025FENCAdherex TechnologiesCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$12.00 ➝ $13.004/24/2025IPHAInnate PharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$11.50 ➝ $11.00(Data available from 6/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAMAMAmbrx Biopharma$7.40M238.95N/AN/A$3.05 per share9.18CMPICheckmate PharmaceuticalsN/AN/AN/AN/A$2.50 per shareN/AFENCAdherex Technologies$47.54M4.79$0.03 per share255.45($0.21) per share-39.29IPHAInnate Pharma$21.77M7.83N/AN/A$0.11 per share16.82Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAMAMAmbrx Biopharma-$78MN/A0.00N/AN/AN/AN/AN/AN/ACMPICheckmate Pharmaceuticals-$61.40M-$2.92N/AN/AN/AN/A-83.92%-74.99%N/AFENCAdherex Technologies-$440K-$0.51N/AN/AN/A-45.52%N/A-26.37%8/12/2025 (Estimated)IPHAInnate Pharma-$53.53MN/A0.00∞N/AN/AN/AN/A9/17/2025 (Estimated)Latest CMPI, IPHA, AMAM, and FENC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025FENCAdherex Technologies-$0.12-$0.04+$0.08-$0.04$8.18 million$8.51 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAMAMAmbrx BiopharmaN/AN/AN/AN/AN/ACMPICheckmate PharmaceuticalsN/AN/AN/AN/AN/AFENCAdherex TechnologiesN/AN/AN/AN/AN/AIPHAInnate PharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAMAMAmbrx BiopharmaN/A13.2813.28CMPICheckmate PharmaceuticalsN/A5.205.20FENCAdherex TechnologiesN/A5.134.97IPHAInnate Pharma2.522.602.60Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAMAMAmbrx Biopharma77.28%CMPICheckmate Pharmaceuticals74.56%FENCAdherex Technologies55.51%IPHAInnate Pharma0.16%Insider OwnershipCompanyInsider OwnershipAMAMAmbrx Biopharma0.64%CMPICheckmate Pharmaceuticals62.60%FENCAdherex Technologies11.76%IPHAInnate Pharma31.89%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAMAMAmbrx Biopharma8763.15 million62.75 millionOptionableCMPICheckmate Pharmaceuticals2822.04 million8.24 millionNot OptionableFENCAdherex TechnologiesN/A27.60 million24.35 millionOptionableIPHAInnate Pharma22092.18 million62.78 millionNot OptionableCMPI, IPHA, AMAM, and FENC HeadlinesRecent News About These CompaniesInnate Pharma (NASDAQ:IPHA) Stock Price Down 1% - Should You Sell?June 18, 2025 | marketbeat.comInnate Pharma Announces Its Participation in H.C. Wainwright and Wolfe Research Healthcare ConferencesJune 17, 2025 | businesswire.comInnate Pharma Highlights Preclinical Antitumor Activity of IPH6501 in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma at the 2025 European Hematology Association (EHA) CongressJune 13, 2025 | businesswire.comInnate Pharma S.A. (NASDAQ:IPHA) Short Interest UpdateMay 30, 2025 | marketbeat.comInnate Pharma Announces Its Participation in Jefferies and Goldman Sachs Healthcare ConferencesMay 27, 2025 | businesswire.comASCO: Innate claims long-term lymphoma data show 'sustained effect' of anti-KIR3DL2 antibodyMay 23, 2025 | fiercebiotech.comFOutcome of Innate Pharma’s 2025 Annual General MeetingMay 23, 2025 | finance.yahoo.comOutcome of Innate Pharma's 2025 Annual General MeetingMay 23, 2025 | businesswire.comInnate Pharma Highlights Durable Responses to Lacutamab in Sezary Syndrome and Mycosis FungoidesMay 23, 2025 | businesswire.comInnate Pharma Highlights Abstracts Selected for ASCO 2025 Annual MeetingMay 19, 2025 | businesswire.comInnate Pharma Highlights ANKET® Abstracts Selected for the EHA 2025 CongressMay 15, 2025 | businesswire.comInnate Pharma S.A. (IPHA) Q1 2025 Earnings Call TranscriptMay 13, 2025 | seekingalpha.comInnate Pharma Reports First Quarter 2025 Business Update and Financial ResultsMay 13, 2025 | businesswire.comInnate Pharma announces conference call and webcast for Q1 2025 business updateMay 6, 2025 | businesswire.comInnate Pharma Files Its 2024 Universal Registration Document (Document d'enregistrement universel) and 2024 Annual Report on Form 20-FApril 30, 2025 | businesswire.comInnate Pharma Unveils Promising Preclinical Data for IPH4502 at AACR 2025April 29, 2025 | tipranks.comInnate Pharma Highlights Preclinical Anti-Tumor Efficacy Data of Its Antibody Drug Conjugate IPH4502 at the AACR 2025 Annual MeetingApril 29, 2025 | businesswire.comInnate Pharma price target lowered to $11 from $11.50 at H.C. WainwrightApril 25, 2025 | markets.businessinsider.comInnate Pharma Announces €15M Investment by SanofiApril 24, 2025 | businesswire.comInnate Pharma Regains Its Rights on CD123 Targeting ANKET® and Announces Sanofi's Intention to Make a Strategic Investment in the CompanyApril 23, 2025 | businesswire.comInnate Pharma to Hold Its Annual General Meeting of Shareholders on May 22, 2025April 16, 2025 | businesswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCMPI, IPHA, AMAM, and FENC Company DescriptionsAmbrx Biopharma NYSE:AMAMAmbrx Biopharma Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing antibody drug conjugates (ADCs) and other engineered therapies to modulate the immune system. It focuses on portfolio of clinical and preclinical programs designed to optimize efficacy and safety in multiple cancer indications, including ARX517, its proprietary antibody-drug conjugate (ADC) targeting the prostate-specific membrane antigen (PSMA) and ARX788, its proprietary ADC targeting HER2. The company also has preclinical and clinical collaborations with multiple partners on drug candidates using Ambrx technology. The company was incorporated in 2003 and is headquartered in La Jolla, California.Checkmate Pharmaceuticals NASDAQ:CMPICheckmate Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing novel therapeutics for the treatment of cancer. It develops CMP-001, which is in phase II clinical trial in combination with pembrolizumab to treat patients with PD-1 refractory melanoma; combination with nivolumab to treat patients with PD-1 naïve neoadjuvant melanoma; and treatment in patients with PD-1 refractory melanoma. Checkmate Pharmaceuticals, Inc. has strategic alliances with Merck KGaA and Pfizer. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.Adherex Technologies NASDAQ:FENC$8.25 -0.03 (-0.36%) Closing price 06/27/2025 04:00 PM EasternExtended Trading$8.22 -0.03 (-0.36%) As of 06/27/2025 04:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Fennec Pharmaceuticals Inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was founded in 1996 and is based in Research Triangle Park, North Carolina.Innate Pharma NASDAQ:IPHA$1.84 -0.07 (-3.40%) As of 06/27/2025 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Innate Pharma S.A., a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. Its products in preclinical trials are IPH43, an anti-MICA/B ADC and IPH45, an antibody drug conjugates (ADC); and IPH67, an undisclosed, multi-specific ANKET. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. Innate Pharma S.A. was incorporated in 1999 and is headquartered in Marseille, France. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Nike Stock: The Mother of All Comebacks Might Have Just Begun EA Just Caught a Monster Upgrade: Bullish Breakout Ahead? Addition by Subtraction: Intel’s New Strategy Energizes Investors Apple: The Mag 7’s Dead Money Stock or AI Cash Cow in the Making? NVIDIA’s Stock Price Hits New Highs: This Is What’s Next Micron: A Hot Buy Heats Up, Fresh All-Time Highs Are Coming Rocket Lab: Europe Comes Calling as Momentum Builds Broadcom’s Big VMware Update: A Threat to Public Cloud Giants? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
